Leukemia drug revumenib data to headline 4 ASCO 2026 talks
Syndax Pharmaceuticals announced that four abstracts related to its leukemia drug, Revuforj (revumenib), have been accepted for presentation at the ASCO 2026 Annual Meeting. These include an oral presentation on post-transplant maintenance data for acute leukemia patients, as well as posters detailing revumenib's pharmacokinetics and the design of two Phase 3 trials for newly diagnosed NPM1m or KMT2Ar AML. The presentations will highlight favorable outcomes and important profiles of the drug, while also reiterating warnings about potential adverse reactions like differentiation syndrome and QTc prolongation.
Assessing Syndax Pharmaceuticals (SNDX) Valuation After New Revuforj Leukemia Data Spurs Investor Interest
Syndax Pharmaceuticals (SNDX) is gaining investor attention following new Revuforj data ahead of the European Hematology Association 2026 Congress, showcasing extensive clinical and real-world results in acute leukemia. Despite a recent share price dip, the stock has shown significant long-term returns, and analysts project a fair value well above its current US$20.13, suggesting it may be undervalued. The positive outlook is driven by late-stage pipeline advancements and strong market positioning in precision oncology.
Syndax Pharmaceuticals’ SWOT analysis: stock gains momentum on strong launch
Syndax Pharmaceuticals has seen significant stock gains following FDA approval and strong commercial performance of its lead product, Revuforj, for acute myeloid leukemia. Despite current losses, the company shows robust revenue growth and a promising pipeline, including axatilimab for graft versus host disease. The analysis highlights both the potential for market expansion and the risks associated with profitability, regulatory warnings, and competition.
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals Inc. (SNDX) announced that its CEO, Michael A. Metzger, and other management team members will participate in three upcoming investor conferences in May and June 2026. These include the TD Cowen 7th Annual Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of the fireside chats will be available on the company's website.
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals, Inc. announced that its CEO, Michael A. Metzger, and other management team members will participate in three upcoming investor conferences: TD Cowen 7th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts of the fireside chats will be available on the company's website, with replays also provided for a limited time. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on advancing innovative cancer therapies, including its FDA-approved drugs Revuforj® and Niktimvo™.
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)?
Syndax Pharmaceuticals recently reported first-quarter 2026 revenue of US$64.86 million and a net loss of US$42.67 million, alongside the acceptance of 12 Revuforj (revumenib) abstracts for the European Hematology Association Congress. This expanded dataset, particularly the real-world ROAR study findings, offers clinical validation for Revuforj, a key asset for Syndax, and could influence its market adoption and the company's financial trajectory. While Syndax projects significant revenue growth and a path to profitability by 2029, investors need to weigh the potential of Revuforj against the company's current losses and reliance on a limited number of commercial assets.
Point72 (SNDX) reports 1,985,547 shares, 2.3% stake in Syndax
Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have reported a shared beneficial ownership of 1,985,547 shares, or a 2.3% stake, in Syndax Pharmaceuticals (SNDX) as of March 31, 2026. This disclosure was made in an amended Schedule 13G filing, indicating shared voting and dispositive power over the shares but no direct ownership by the reporting persons. The filing clarifies the organizational structure, with Point72 Asset Management acting as the investment manager and Mr. Cohen controlling both entities.
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Syndax Pharmaceuticals (SNDX) is highlighted as a top small-cap stock with 10x potential, following a reaffirmed Buy rating and increased price target from Stifel. The company reported strong Q1 2026 results, driven by significant revenue growth from its cancer therapies, Revuforj and Niktimvo. Syndax also anticipates new data releases for its ongoing clinical trials in Q2 and Q4 2026.
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)?
Syndax Pharmaceuticals reported first-quarter 2026 revenue of US$64.86 million and a net loss of US$42.67 million. The company highlighted 12 Revuforj (revumenib) abstracts for presentation at the June 2026 European Hematology Association Congress, showcasing its activity across acute leukemia settings and genetic subtypes. This expanded real-world data, particularly from the ROAR study, is crucial for validating Revuforj's potential for broader use and influencing Syndax's path toward profitability, as analysts project significant revenue growth and a positive earnings shift by 2029.
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Syndax Pharmaceuticals (SNDX) is highlighted as a top small-cap stock with 10x potential, following a price target increase by Stifel to $46. The company recently reported a 224% year-over-year revenue increase in Q1 2026, driven by strong sales of its cancer therapies Revuforj and Niktimvo. Upcoming data releases for revumenib and axatilimab trials in fiscal Q2 and Q4 2026 are expected to further drive growth.
UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating
UBS has adjusted its price target for Syndax Pharmaceuticals, lowering it to $37 from the previous $38. Despite this minor reduction, the firm has maintained its "Buy" rating on the stock. This indicates a continued positive outlook on Syndax Pharmaceuticals by UBS, albeit with a slightly revised valuation.
UBS Trims Price Target on Syndax Pharmaceuticals to $37 From $38, Maintains Buy Rating
UBS has adjusted its price target for Syndax Pharmaceuticals (SNDX) to $37, down from $38, while retaining a "Buy" rating on the stock. This update comes as Syndax Pharmaceuticals reported its Q1 2026 financial results, showing a narrowed loss and increased revenue. The company is actively developing cancer therapies, including Revuforj and Niktimvo, positioning itself in the biotechnology and medical research sector.
Syndax Pharmaceuticals stock (US88906L1052): Analyst upgrade drives 6.6% gain
Syndax Pharmaceuticals (NASDAQ: SNDX) saw a 6.6% stock increase on May 4, 2026, driven by an analyst upgrade and its robust menin inhibitor pipeline. Twelve abstracts related to its lead candidate, Revuforj (revumenib), have been accepted for the European Hematology Association (EHA) 2026 conference, highlighting its scientific advancements. The company, a clinical-stage oncology firm, beat Q1 2026 EPS estimates and holds a "Moderate Buy" consensus rating from analysts, with a target price suggesting significant upside as it progresses toward potential commercialization.
Leukemia drug revumenib lands 12 studies at European Hematology meeting
Syndax Pharmaceuticals announced that 12 abstracts for its leukemia drug, Revuforj (revumenib), have been accepted for presentation at the European Hematology Association (EHA) 2026 Congress. These studies cover various acute leukemia settings, including real-world data, frontline treatments, relapsed/refractory cases, and post-transplant maintenance, reinforcing Revuforj's role as a menin inhibitor. The announcement details the scope of these presentations and includes important safety information regarding differentiation syndrome and QTc prolongation associated with the drug.
Syndax Highlights 12 Revuforj® (revumenib) Abstracts
Syndax Pharmaceuticals highlighted the release of 12 abstracts for its drug Revuforj (revumenib) for presentation at the European Hematology Association (EHA) 2026 Congress. These abstracts demonstrate Revuforj's strong activity across acute leukemia treatment stages and genetic subtypes, including encouraging results in post-transplant settings and for relapsed/refractory NUP98r acute leukemia. The data underscore Syndax's leadership in menin inhibition and aim to inform physician decision-making and ongoing clinical trials.
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Stronger Revenue And Narrower Losses
Syndax Pharmaceuticals (SNDX) reported significantly stronger first-quarter 2026 revenue of US$64.86 million, up from US$20.04 million year-over-year, and narrowed its net loss to US$42.67 million. Despite recent mixed share price action, including a 7.67% gain over 7 days but a 12.07% drop over 30 days, the company shows strong long-term momentum with a 95.54% shareholder return over the past year. The article highlights a narrative suggesting Syndax is 45.6% undervalued, with a fair value of $39.50 compared to its last close of $21.49, driven by expanding product sales and pipeline advancements in precision oncology.
SNDX Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Syndax Pharmaceuticals Inc (SNDX), detailing its revenue breakdown, profitability margins, and a comparison with competitors. SNDX boasts a high gross margin of 95.94% but currently shows negative operating and net margins, along with a negative Return on Equity (ROE) of -189.53%. The company, with a market capitalization of $1.90B, competes with industry leaders like GENB and ALMR.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement grants to eight new employees for up to 162,100 shares of common stock under its 2023 Inducement Plan. These stock options will vest over four years, tied to the employees' continued service with the company. Syndax is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, with approved products like Revuforj and Niktimvo.
SNDX SEC Filings - Syndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Syndax Pharmaceuticals Inc.'s (NASDAQ: SNDX) official SEC filings, including annual 10-K reports, quarterly 10-Q statements, and 8-K material event disclosures. It highlights recent significant filings such as FDA approval for Revuforj and board changes, offering investors key insights into the company's financial performance, regulatory milestones, and governance. The platform also features AI-powered tools for navigating complex document language and provides summaries, impact scores, and sentiment analysis for each filing.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement awards for new employees on May 1, 2026, comprising options to purchase up to 162,100 shares of common stock. These options, granted under the Company's 2023 Inducement Plan, will vest over four years, with a portion vesting after one year and the remainder monthly thereafter, contingent on continued employment. Syndax is a biopharmaceutical company focused on innovative cancer therapies, with FDA-approved products Revuforj and Niktimvo.
Eight new Syndax hires get stock options for 162,100 shares
Syndax Pharmaceuticals granted inducement awards to eight new employees on May 1, 2026, for up to 162,100 shares under its 2023 Inducement Plan. The stock options will vest over four years, with a 25% cliff vesting at one year followed by monthly vesting for 36 months, subject to continued employment. This move highlights the company's strategy to attract and retain talent through equity compensation.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals announced inducement grants on May 1, 2026, for up to 162,100 shares of common stock to eight new employees under its 2023 Inducement Plan. The stock options will vest over four years, with a quarter vesting after one year and the remainder monthly over 36 months, contingent on continued employment. Syndax is a commercial-stage biopharmaceutical company focused on cancer therapies, including FDA-approved Revuforj® and Niktimvo™.
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $46
Stifel analyst Stephen Willey has reiterated a Buy rating for Syndax Pharmaceuticals (SNDX.US) and increased its target price from $44 to $46. This adjustment reflects the analyst's positive outlook on the company, with Willey holding a 43.6% success rate and a 9.5% average return over the past year according to TipRanks data.
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings
HC Wainwright has revised its Q2 2026 EPS estimates for Syndax Pharmaceuticals (NASDAQ:SNDX) upward, reducing projected losses and forecasting a return to profitability by FY2028-FY2029. Syndax Pharmaceuticals beat Q1 EPS estimates and saw significant revenue growth, though it remains unprofitable. The market outlook is cautiously bullish, with analysts assigning a "Moderate Buy" rating and a consensus target price of $40.50, while insiders have recently sold shares.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Syndax Pharmaceuticals (NASDAQ:SNDX) experienced a 5.0% share drop after its first-quarter results, with revenue falling short of estimates at US$65m, though statutory losses were better than expected at US$0.48 per share. Analysts are forecasting a major 60% increase in revenues to US$346.4m in 2026, with losses per share expected to narrow by 41% to US$1.63, indicating an anticipated acceleration in growth significantly faster than the industry average. Despite revised revenue estimates, the average price target remained steady at US$39.58, suggesting no long-term impact on valuation from these latest results.
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Syndax Pharmaceuticals recently released its first-quarter earnings, showing a significant miss on revenue expectations but a beat on statutory earnings per share. Analysts have since revised their price targets and forecasts for the company, reflecting a mixed outlook despite the earnings report. The consensus among analysts remains a "buy," with an average price target indicating substantial upside potential.
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade
Syndax Pharmaceuticals (NASDAQ:SNDX) saw its stock price rise by 6.6% after Barclays raised its price target from $35 to $37, maintaining an "overweight" rating. Several other firms also increased their price targets, contributing to a "Moderate Buy" consensus rating with an average target of $40.50. Despite recent insider stock sales and missing revenue estimates in its latest earnings report, the company did beat EPS expectations and reported strong year-over-year revenue growth.
Syndax Pharmaceuticals (SNDX) Is Down 10.7% After Revenue Surges And Loss Narrows In Q1 2026
Syndax Pharmaceuticals (SNDX) reported a significant revenue increase to US$64.86 million and a narrowed net loss of US$42.67 million in Q1 2026, driven by sales of Revuforj and Niktimvo. Despite these improvements and better operating leverage, the company's investment narrative remains dependent on upcoming clinical and regulatory readouts for its two commercial assets. Management forecasts 2026 operating expenses around US$400 million, highlighting the importance of incremental revenue from product sales and label expansions to further reduce losses.
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives
Syndax Pharmaceuticals (SNDX) reported a Q1 2026 net loss of US$42.7 million on revenues of US$64.9 million, showing a reduction in losses compared to previous quarters as its commercial model scales. Despite ongoing losses, analysts project a shift to profitability within three years, driven by revenue growth and cost discipline. The company's stock trades below industry averages, with a DCF fair value significantly higher than its current share price.
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives
Syndax Pharmaceuticals (SNDX) reported a narrowed Q1 2026 net loss of US$42.7 million on revenues of US$64.9 million, showing progress towards profitability. The company aims to shift from a 165.6% loss to a 14.7% profit margin in three years, despite a current trailing twelve-month loss of US$243.2 million. While bullish investors highlight strong forecast growth and a P/S discount compared to peers, bearish arguments focus on high R&D costs and dependence on a few lead drugs.
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3
This article displays the net current asset value per share for Syndax Pharmaceuticals Inc (DUS:1T3). The content is a financial data point from TradingView, part of the company's financial overview on the Dusseldorf Stock Exchange. It includes standard disclaimers about data providers and copyright.
Syndax Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Syndax Pharmaceuticals Inc. has released its earnings summary for the quarter that ended on March 31. This report provides an overview of the company's financial performance during that period. The information is distributed by Refinitiv.
Syndax Pharmaceuticals (NasdaqGS:SNDX) Stock Forecast & Analyst Predictions
Syndax Pharmaceuticals (SNDX) is forecast to achieve significant earnings and revenue growth, with analysts projecting a 67.7% annual earnings increase and 30.5% revenue growth. The company is expected to become profitable within the next three years, with a high return on equity forecast at 446.2%. Recent updates focus on regulatory approvals for Revuforj and Niktimvo, upcoming trial readouts, and adjusted price targets as analysts factor in new research and market developments.
A Look At Syndax Pharmaceuticals (SNDX) Valuation As Q1 2026 Results Refocus Investor Attention
Syndax Pharmaceuticals (SNDX) has garnered renewed investor attention following its Q1 2026 results, reporting $64.86 million in revenue and a reduced net loss. Despite a 39.18% return over the past year, the stock saw a negative 19.97% return in the last month. The company's valuation narrative suggests it is 51.6% undervalued with a target price of $39.50, driven by pipeline advancements and market-leading positions, though market ratios present a more cautious outlook on its P/S of 11x compared to industry averages and Simply Wall St's fair ratio.
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?
Syndax Pharmaceuticals (NASDAQ:SNDX) saw its stock price drop by 7.1% on Friday, trading at $19.91 with significantly lower-than-average volume. Despite beating Q1 EPS estimates, the company missed revenue expectations, though quarterly revenue was up 224%. Analysts maintain an overall "Moderate Buy" consensus rating with an average target price of $40.50, and recent insider selling by the CFO and CEO has been noted.
Syndax (NASDAQ: SNDX) triples revenue as Revuforj and Niktimvo ramp
Syndax Pharmaceuticals (NASDAQ: SNDX) reported a significant increase in revenue for Q1 2026, reaching $64.9 million, more than triple the $20.0 million from the previous year, driven by strong sales of their cancer drugs Revuforj and Niktimvo. While the company remains unprofitable, narrowing its net loss to $42.7 million from $84.8 million year-over-year, it maintains a solid cash position of $352.1 million to support ongoing commercialization and development. Syndax anticipates further growth for Revuforj and Niktimvo, with multiple clinical trial data readouts expected throughout 2026 for new indications and combinations, alongside continued high R&D spending.
Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss
Syndax Pharmaceuticals (SNDX) reported a Q1 loss of $0.48 per share, which is better than FactSet's estimated loss of $0.61 per share. The company is a clinical-stage biopharmaceutical firm focused on developing cancer therapies, with product candidates including revumenib and axatilimab. They also reported Q1 revenue of $64.9 million, falling short of FactSet's estimate of $69.8 million.
[8-K] Syndax Pharmaceuticals Inc Reports Material Event
Syndax Pharmaceuticals Inc. reported a significant increase in Q1 2026 revenue, reaching $64.9 million, a 224% year-over-year jump, primarily driven by strong launches of their drugs Revuforj and Niktimvo. Despite remaining loss-making, the company significantly narrowed its net loss to $42.7 million from $84.8 million a year prior. Syndax projects a path to profitability, anticipating its current cash, investments, and revenue streams will sufficiently cover operating expenses for 2026.
Syndax: Q1 Earnings Snapshot
Syndax Pharmaceuticals Inc. (SNDX) reported a first-quarter loss of $42.7 million, or 48 cents per share, which exceeded Wall Street expectations. While the company's loss per share was better than analysts predicted, its revenue of $64.9 million fell short of forecasts.
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q1 Revenue $64.9M, vs. FactSet Est of $69.8M
Syndax Pharmaceuticals, Inc. (SNDX) reported its Q1 revenue at $64.9 million, falling short of the FactSet estimate of $69.8 million. The company's Q1 earnings also showed a loss of $0.48 per share, which was better than FactSet's estimated loss of $0.61 per share. Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies, including revumenib and axatilimab.
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported strong first-quarter 2026 financial results, with total revenue reaching $64.9 million, a 224% year-over-year increase. This growth was driven by Revuforj and Niktimvo net sales, which combined for over $100 million, pushing the company closer to profitability. The company also anticipates significant clinical milestones, including new data for Revuforj in various acute leukemia settings and topline data from Phase 2 trials of Niktimvo in IPF and newly diagnosed chronic GVHD later in 2026.
Syndax Pharmaceuticals earnings face test as competition heats up By Investing.com
Syndax Pharmaceuticals is set to report its first-quarter earnings, with investors focused on the commercial performance of its cancer drugs, Revuforj and Niktimvo, amidst rising competition. Analysts anticipate a loss of 62 cents per share on revenue of $71.8 million, marking an improvement from the previous quarter. The company aims for profitability without additional financing and awaits crucial Phase 2 trial data for axatilimab in idiopathic pulmonary fibrosis in late 2026.
Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Thursday
Syndax Pharmaceuticals (SNDX) is expected to announce its Q1 2026 earnings before market open on Thursday, April 30th, with analysts forecasting an EPS of ($0.59) and revenue of $72.664 million. The company reported mixed results last quarter, missing EPS but significantly increasing revenue year-over-year. The stock currently has a "Moderate Buy" consensus rating and a target price of $40.33, despite recent insider share sales.
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals (Nasdaq: SNDX) will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Details for accessing the webcast and conference call, including a replay option, are provided.
Earnings Preview: SNDX to Report Financial Results Post-market on April 30
This article previews Syndax Pharmaceuticals (SNDX) upcoming financial results report for the quarter ending March 31, 2026, which is scheduled for post-market release on April 30. Analysts expect a GAAP EPS of -$0.98. The company missed EPS estimates in three of the last four quarters.
Syndax Pharmaceuticals to Announce Q1 2026 Financial Results and Business Update on April 30, 2026
Syndax Pharmaceuticals will release its first-quarter 2026 financial results and provide a business update on April 30, 2026. The company will host a conference call and audio webcast at 4:30 p.m. ET on that day, accessible via their website or designated phone numbers. A replay will be available for 90 days after the call, and Syndax highlights its pipeline of innovative cancer therapies, including FDA-approved Revuforj® and Niktimvo™.
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals (Nasdaq: SNDX) announced it will report its first-quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results. A replay of the webcast will be available on the Investors section of Syndax's website for 90 days following the call.
Syndax to post quarterly results April 30, webcast starts at 4:30 p.m. ET
Syndax Pharmaceuticals (Nasdaq: SNDX) announced it will report its first-quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET. A replay of the call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals (Nasdaq: SNDX) will announce its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET, accessible via their website's Investors section or by dial-in. A replay will be available for 90 days after the call.
(SNDX) Movement as an Input in Quant Signal Sets
This article analyzes Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) using AI models to generate trading strategies and multi-timeframe signal analysis. It notes weak near and mid-term sentiment but a strong long-term outlook, identifying potential entry, target, and stop-loss zones for various trading styles. The analysis highlights an elevated downside risk with no additional long-term support signals.
